alzecurepharma-project-overview-header

Project overview

AlzeCure Pharma is developing novel therapies based on two different programs – NeuroRestore and Alzstatin – that are targeting two characteristic hallmarks of Alzheimer’s disease: cognitive dysfunction and accumulation of amyloid plaques in the brain.

In addition to the front-runner compounds in these program – ACD855 (NeuroRestore) and ACD679 (Alzstatin) – additional compounds are being developed which will provide several opportunities to reach the market.

AlzeCure Pharma’s Pipeline

Project overview